| Presenters - 2011 |
December 2011
Algaeon William Kassebaum Phone: 317-225-4180 x1 Vision: Algaeon, Inc. is committed to becoming the preeminent producer of high-quality, renewable and sustainable fuels from algae. Our goal is to reshape the energy landscape by providing a new domestic source of eco-friendly renewable energy.
Products: The Company’s fuel products are compatible drop-in replacements for all of the commonly used transport fuels.
• Gasoline, Kerosene, Diesel, Fuel oil, Butanol, Ethanol, Avgas – zero lead content, Jet-A - superior Jet Fuel
Business Summary: Algaeon, Inc. has developed patent pending industrial scale microalgae cultivation technology to feasibly grow, harvest and process commercially significant quantities of renewable drop-in replacement fossil fuel substitutes. The company intends to demonstrate its technology at commercial scale and subsequently commercialize by integrating the supply chain and growing a network of farm licensees around the world.
Key Differentiation: • Algae industry has been missing commercially scalable, high capacity production methods that yield competitively priced refinery feedstock. Algaeon has solved the remaining hurdles to commercially viable algae-based fuel production through a unique and proprietary production process – the algae vertical vineyard -while consuming and recycling carbon dioxide.
• This processing solution is coupled with an innovative business model that makes licensed algae oil production an attractive cash crop for farmers, enabling rapid, capital-efficient scaling.
• Algaeon has unique relationships to produce and distribute unblended ASTM certified AvGas and Jet Turbine fuel products made from 100% algae derived feedstocks.
Feasibility Shown: • Algaeon has built and is operating a feasibility-scale microalgae production facility.
• Refined fuels (avgas and jet turbine fuel) produced by the Company’s partner, using feedstocks derivable from Algaeon’s microalgae, have been tested and analyzed. The AvGas has passed ASTM D910 certification and the jet turbine fuel has been shown to be certifiable under ASTM D7566 as an unblended fuel.
• Limited international licensing arrangements for the algae vertical vineyard are currently being negotiated. Next Steps for Algaeon: • Algaeon is seeking financing to construct and operate a pilot scale production integration facility over the next year and to construct a commercial-scale, financially self-sustaining production facility in 2013/2014 to pave the way for its back log of licensees in setting up turn-key operations of their own.
Phone:502-298-3411
|
|
Mark A. Wisniewski Chief Operating Officer Louisville Bioscience Inc. Office: 502.742.1159 Mobile: 310.422.6776 This e-mail address is being protected from spambots. You need JavaScript enabled to view it |
Strategic Overview / Value Proposition: Propelled by significant Federal and State support Louisville Bioscience Inc. (LBIdxTM) is raising $5 million in a Series A financing round. This will capitalize completion of development and commercialization of our reference laboratory test for differential diagnosis of Autoimmune diseases. By 2012, LBIdxTM will launch this first reference test; and by 2015 generate more than $100 million in revenue.
LBIdxTM has made a significant breakthrough in the analysis of blood plasma using Differential Scanning Calorimetry (DSC) to diagnose clinical samples. Remarkably, every disease measured generates a distinctive and characteristic Plasma ThermogramTM that is statistically different from healthy "normal" individuals. The Company has generated compelling clinical data for numerous disease conditions including autoimmune diseases and various cancers. Validation of acquired clinical data through independent statistical analyses by a world-renowned expert has confirmed strategic goals. The strategic focus of the Company and clinical development efforts have also been driven by key stakeholder relationships within the scientific, clinical and business communities. LBIdxTM will utilize the low-overhead CLIA Laboratory model to rapidly develop and commercialize new diagnostic tests into high-volume sales within the target markets of Autoimmune Disease Differentiation and Oncology Treatment Monitoring. The first test to be commercialized will differentially diagnose autoimmune conditions such as Lupus, Multiple sclerosis, Rheumatoid arthritis, Scleroderma and Polymyositis (together 20% of the U.S. population). These diseases are all commonly misdiagnosed with one another. Since DSC analysis of biological fluids comprises a novel proprietary platform, in the future, much broader applications may be realized including biomarker discovery, drug target identification and screening.
Science / Technology: LBIdxTM Plasma ThermogramsTM arise from the temperature-induced denaturation i.e. melting profile of the protein mixture within the blood plasma measured by DSC. This fundamental physical technology ascertains dominant constituents of blood plasma and serum, and interactions therein, which can be used as sensitive and specific indicators of disease states. DSC provides a fundamental and quantitative physical measurement of temperature-induced transitions and melting points offering an entirely new window through which to explore the plasma proteome. This novel information is complementary to serum protein electrophoresis and mass spectrometry, which analyze plasma proteins based on size and charge.
Competitive Advantage: The Plasma ThermogramTM assay is a robust physical test with high assay reproducibility. It is inexpensive, non-invasive, requires only a single drop of blood, and can be performed within an hour.
Market Opportunity: Many prevalent autoimmune diseases are misdiagnosed with each other. These include: Lupus, Multiple sclerosis and Rheumatoid arthritis making differential diagnosis an important unmet medical need, and critical to timely and accurate treatment. Most cancers are only detected at advanced stages and so are ineffectively monitored, limiting treatment outcomes and resulting in high rates of advanced morbidity and mortality. As a breakthrough diagnostic tool multiple applications exist for the Plasma ThermogramTM technology including: (1) Early stage disease detection; (2) Distinction between different stages of disease; (3) Monitoring disease progression, remission and relapse; (4) Assessing effectiveness of treatment regimen; (5) Identification of therapeutic targets for drug development. A billion dollar market opportunity exists for the LBIdxTM Plasma ThermogramTM platform achieved through high-volume testing combined with premium pricing and lifelong periodic monitoring of autoimmune diseases and cancer.
IP Portfolio: LBIdxTM owns an exclusive worldwide license from the University of Louisville for all commercial uses to two broad US and PCT patent applications that cover Plasma ThermogramsTM for diagnostic analysis, biomarker discovery and therapeutic monitoring. In addition, LBIdxTM owns one US patent application for proprietary computational analysis of Plasma ThermogramsTM. An aggressive IP strategy is being implemented to protect IP generated throughout development including: the full turn-key diagnostic system, proprietary analytical software methodologies, a robust reference database of disease Plasma ThermogramsTM and consumable kits for specific diagnostic tests.
The Company / Management Team: The Plasma ThermogramTM technology was invented at the University of Louisville by: Drs. Jonathan B. Chaires, James Graham Brown Endowed Chair in Cancer Biophysics, Nichola C. Garbett and A. Bennett Jenson of the Clinical and Translational Sciences Institute. Dr. Jenson is a board certified pathologist and was previously a Founder of Digene Corp. (acquired by Qiagen for $1.6 billion) and inventor of the Merck & Co. blockbuster HPV vaccine, Gardasil.
The LBIdxTM management team is comprised of experienced individuals with successful business track records, highly relevant experience and substantial scientific achievements.
Fund Raising / Revenue Model: LBIdxTM is seeking to raise $5 million in a Series A round to support near-term strategic goals: product development and commercialization of the first test. Bolstered by past success, it is expected that a significant portion of funding for ongoing product development tasks will come from various non-dilutive Federal and State grants. Driven by initial clinical development activities (2009-2012), we expect a new Plasma ThermogramTM assay to be commercialized each year thereafter. The revenue stream will commence in 2012 with the launch of our Plasma ThermogramsTM “Reference Use Only” test for differential diagnosis of Lupus, Multiple sclerosis, Rheumatoid arthritis, Scleroderma and Polymyositis.
For further information please contact:
|
Albert S. Benight President
Louisville Bioscience Inc. Office: 502.742.1159 Mobile: 503.916.9466 This e-mail address is being protected from spambots. You need JavaScript enabled to view it |
Michael P. Birdsell Vice President Marketing and Alliances
Louisville Bioscience Inc. Office: 502.742.1159 Mobile: 530.414.0286 This e-mail address is being protected from spambots. You need JavaScript enabled to view it |
Mark A. Wisniewski Chief Operating Officer
Louisville Bioscience Inc. Office: 502.742.1159 Mobile: 310.422.6776 This e-mail address is being protected from spambots. You need JavaScript enabled to view it |
Emily Gimmel
CEO
Phone: 702-499-5372
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Executive Summary
Most computer bags are either too corporate, tac ky or sporty. The TAXI solution is to produce and sell high fashion, affordable tablet and laptop carriers that enhance outfits instead of disrupting them. We will appeal to young, modern professionals who know that true luxury is not about high prices and excess, it about value and freedom. Products will be available on our website, Fac ebook, other online stores, at specialty events, and in select boutiques. We have already acquired letters of intent from two major retailers who will sell our products.
The potential growth for our market is global, due to the rise of 3G and 4G networks and national broadband initiatives. 1.9 billion people are online worldwide. Apple expects to sell 100 million iPads by the end of 2011. Ten other tablet devices are expec ted to launch in 2011 alone. It's proven that small luxuries are very popular in recessions. The handbag market in the US alone is expec ted to grow 20 percent to $8.2 billion by 2012.
Our structure is completely scalable and we don't spend money unless we make money.
We use automated technologies and third party alliances to operate with minimal overhead.
Designs are made by an experienced ac cessories designer and manufactured in China by a British owned company that is a top supplier for Europe and North America. Products will be
warehoused in a leading fulfillment center in Louisville, KY, the home of UPS and best location for shipping in America. Inventory is tracked through a computerized system to ensure accuracy. A digital sales team works off commission to push our products ac ross the web. A leading call center will handle phone support. This enables us to focus on marketing and connecting with our customers.
Social commerce is a game changer for online retail and is the center of our marketing
strategy. It's proven that the more time someone spends on Facebook, the more money they
spend online. We utilize Emily's established viral fan base to sell products. We will also leverage Emily's personal relationships with celebrities, journalists and executives to get products into the hands of influencers. A world famous male supermodel will be a spokesmodel for the brand, increasing credibility and buzz. We will participate in technology conferences, media issues and events that promote digital innovation. A portion of sales will be donated to a charity that establishes the Internet in poor communities.
A survey of 135 top retail CEOs reveals 74% say they'll search for leadership positions outside the industry in the next five years. They seek new prospectives on connecting with consumers and state that the most important retail leadership skills are strategic, not experiential. TAXI will connect with c onsumers by applying persuasive viral marketing, targeted advertising and the knowledge of how to capitivate an audience.
The amount required to start is $250,000. We will enter the market three months after we
finish fundraising.